Search for content, post, videos

Jan Lundberg invests in Sigrid Therapeutics

Jan Lundberg

Sigrid Therapeutics has announced that pharmaceutical R&D leader, Dr. Jan Lundberg has joined the company as an investor and member of the Scientific Advisory Board.

Jan Lundberg has more than 20 years of leadership experience from executive positions in the global pharmaceutical companies AstraZeneca (1996-2009) and Eli Lilly (2010-2018). He has overseen the development of more than 200 candidate drugs, with 25 approved products across multiple therapeutic areas.

Before joining AstraZeneca, Lundberg held the position of Professor of Pharmacology at the Karolinska Institute in Solna, Sweden. His research achievements led to the publication of 500 articles in peer reviewed scientific journals.

Read more: Jan Lundberg: The long view of R&D at Eli Lilly

“Sigrid has developed a very promising technology with the potential to improve the lives of millions of people suffering from obesity and at risk of developing type 2 diabetes. I am excited to join the company at this stage of development and look forward to contributing to the team’s continued success,” says Lundberg.

Vast R&D and business experience

Lundberg also serves on the boards of Ardelyx, Metabolon, TB Alliance, Imaging Analysis Group, Anocca and Betagenon. He has also been a member of several governmental committees in both the European Union and the United States.

“We are absolutely delighted to welcome Dr. Jan Lundberg as an investor and member of Sigrid’s Scientific Advisory Board,” says Sana Alajmovic, Co-founder & CEO, Sigrid Therapeutics. “Dr. Lundberg’s vast R&D and business experience will be invaluable in advancing our first product to market within the next 2 years.